Immunic Highlights IMU-856 Gastrointestinal Candidate to Mark International Celiac Day
Immunic Highlights IMU-856 Gastrointestinal Candidate to Mark International Celiac Day
Key Takeaways (TLDR)
Immunic Inc is developing IMU-856, an epigenetic modulator, to treat celiac disease, potentially gaining an edge in the market.
IMU-856 enhances gut regeneration and strengthens the gut barrier, improving patients' conditions by treating celiac disease at its root cause.
IMU-856 has the potential to make a significant positive impact on the lives of celiac disease patients, offering a more effective treatment than a gluten-free diet.
Celiac disease is a severe autoimmune disorder affecting around 1% of the global population, predominantly females, highlighting the importance of raising awareness and advancing treatment options.
Why it Matters
Celiac disease affects a significant portion of the global population, and the only current treatment is a gluten-free diet, which is not effective for all patients. Immunic's development of IMU-856 offers hope for improving the conditions of celiac disease patients and potentially providing a more effective treatment option.
Summary
Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof discussed the company’s developments in treating celiac disease on International Celiac Day. Celiac disease is a severe autoimmune disorder affecting around 1% of the global population. Immunic is developing IMU-856, an epigenetic modulator, to treat gastrointestinal diseases like celiac disease.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Immunic Highlights IMU-856 Gastrointestinal Candidate to Mark International Celiac Day.